Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as perillyl alcohol, work in different ways to
stop the growth of abnormal cells, either by killing the cells or by stopping them from
dividing. It is not yet known which dose of topical perillyl alcohol is more effective in
stopping the development of cancer in sun damaged skin.
PURPOSE: This randomized phase II trial is studying high-dose topical perillyl alcohol to see
how well it works compared with low-dose topical perillyl alcohol in treating patients with
sun damaged skin and actinic keratoses.
Phase:
Phase 2
Details
Lead Sponsor:
University of Arizona
Collaborators:
Arizona Disease Control Research Commission National Cancer Institute (NCI)